<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-30T03:23:54Z</responseDate><request verb="GetRecord" identifier="oai:riubu.ubu.es:10259/7559" metadataPrefix="mods">https://riubu.ubu.es/oai/request</request><GetRecord><record><header><identifier>oai:riubu.ubu.es:10259/7559</identifier><datestamp>2023-04-18T12:48:15Z</datestamp><setSpec>com_10259_3924</setSpec><setSpec>com_10259_5086</setSpec><setSpec>com_10259_2604</setSpec><setSpec>col_10259_3925</setSpec></header><metadata><mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:namePart>Espona Fiedler, Margarita</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Manuel Manresa, Pilar</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Benítez-García, Cristina</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Fontova Pale, Pere</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Quesada Pato, Roberto</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Soto Cerrato, Vanessa</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Pérez Tomás, Ricardo</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2023-03-20T08:26:03Z</mods:dateAvailable>
</mods:extension>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2023-03-20T08:26:03Z</mods:dateAccessioned>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2022-12</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="uri">http://hdl.handle.net/10259/7559</mods:identifier>
<mods:identifier type="doi">10.3390/pharmaceutics15010097</mods:identifier>
<mods:identifier type="essn">1999-4923</mods:identifier>
<mods:abstract>Metastasis is the primary cause of death in cancer patients. Many current chemotherapeutic&#xd;
agents only show cytotoxic, but not antimetastatic properties. This leads to a reduction in tumor&#xd;
size, but allows cancer cells to disseminate, which ultimately causes patient death. Therefore, novel&#xd;
anticancer compounds with both effects need to be developed. In this work, we analyze the antimetastatic properties of prodigiosin and obatoclax (GX15-070), anticancer drugs of the Prodiginines&#xd;
(PGs) family. We studied PGs’ effects on cellular adhesion and morphology in the human primary&#xd;
and metastatic melanoma cell lines, SK-MEL-28 and SK-MEL-5, and in the murine melanoma cell&#xd;
line, B16F10A. Cell adhesion sharply decreased in the treated cells, and this was accompanied by a&#xd;
reduction in filopodia protrusions and a significant decrease in the number of focal-adhesion structures. Moreover, cell migration was assessed through the wound-healing assay and cell motility was&#xd;
severely inhibited after 24 h of treatment. To elucidate the molecular mechanisms involved, changes&#xd;
in metastasis-related genes were analyzed through a gene-expression array. Key genes related to&#xd;
cellular invasion, migration and chemoresistance were significantly down-regulated. Finally, an&#xd;
in vivo model of melanoma-induced lung metastasis was established and significant differences in&#xd;
lung tumors were observed in the obatoclax-treated mice. Altogether, these results describe, in depth,&#xd;
PGs’ cellular antimetastatic effects and identify in vivo antimetastatic properties of Obatoclax.</mods:abstract>
<mods:language>
<mods:languageTerm>eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by/4.0/</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">info:eu-repo/semantics/openAccess</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">Atribución 4.0 Internacional</mods:accessCondition>
<mods:subject>
<mods:topic>Metastasis</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Obatoclax</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Prodigiosin</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Prodiginines</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>BH3-mimetic</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Melanoma</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Migration</mods:topic>
</mods:subject>
<mods:titleInfo>
<mods:title>Antimetastatic Properties of Prodigiosin and the BH3-Mimetic Obatoclax (GX15-070) in Melanoma</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods></metadata></record></GetRecord></OAI-PMH>